Emergent BioSolutions Inc. (EBS) Q2 FY26 Earnings Call

MCM strength and $40 million savings are offset by worsening Narcan competition and a sharply reduced 2026 outlook.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-05
Length36 minutes
EPS$0.60
Revenue$156.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All EBS earnings ยท Back to EBS overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.